Extended‐Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent form of heart failure, representing half of the total burden of heart failure. We hypothesised that modulation of the phosphodiesterase type 3/cyclic AMP using a novel oral formulation of milrinone might...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanayakkara, Shane, Byrne, Melissa, Mak, Vivian, Carter, Kaye, Dean, Eliza, Kaye, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670502/
https://www.ncbi.nlm.nih.gov/pubmed/32552264
http://dx.doi.org/10.1161/JAHA.119.015026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670502/
https://www.ncbi.nlm.nih.gov/pubmed/32552264
http://dx.doi.org/10.1161/JAHA.119.015026

Ejemplares similares